Eosinophils are innate immune leukocytes involved in host protection against helminth infections, yet under different circumstances, eosinophils can be proinflammatory effector cells through their inappropriate localization, activation, and release of proinflammatory substances and can contribute to the pathophysiology of disorders, including asthma, rhinitis, certain gastrointestinal disorders, and atopic dermatitis. 1, 2 Current treatments for these conditions include mediator antagonists, glucocorticosteroids, biologics, and other anti-inflammatory drugs that reduce allergic cell numbers and inhibit mediator functions, but they are neither fully effective nor curative or disease modifying. 3, 4 Thus it remains essential to identify additional targets on these and other allergic effector cells for therapeutic exploitation.
Sialic acid-binding immunoglobulin-like lectins (Siglecs) are single-pass transmembrane cell-surface proteins found predominantly on leukocytes and are characterized by their ability to bind specific sialic acid structures. The Siglec family is divided into 2 subsets, a highly conserved subset and a rapidly evolving CD33-related subset, the latter of which includes Siglec-8. 5, 6 Siglec-8 is an eosinophil-selective surface receptor that contains an intracellular immunoreceptor tyrosine-based inhibitory motif (ITIM) and an immunoreceptor tyrosine-based switch motif thought to be responsible for inhibitory signal transduction. [7] [8] [9] Previous work has shown that multimeric engagement of Siglec-8 on normal, non-cytokine-primed eosinophils causes apoptosis in a caspase-dependent manner. 10 However, in IL-5-primed human eosinophils, Siglec-8 engagement induces loss of mitochondrial membrane potential and reactive oxygen species (ROS) production, enhances activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway, and results in apoptosis that is instead dependent on mitochondrial damage and ROS production. [11] [12] [13] [14] This suggests that Siglec-8 can function as an activating receptor.
The intracellular mechanisms and pathways of signaling for most Siglecs are not well understood. Several studies have shown that antibody binding of CD33-related Siglecs leads to rapid phosphorylation of Src family kinases that mediate the recruitment of, for example, Src homology region 2 domain-containing phosphatases 1 and 2, presumably to intracellular Siglec ITIM domains. [15] [16] [17] [18] [19] In an effort to more fully characterize the signaling mechanisms mediated through Siglec-8, we discovered that its engagement on eosinophils leads to rapid enhancement of eosinophil adhesion that is entirely b 2 -integrin mediated and requires IL-5 priming. We also show that blocking of b 2 -integrins in IL-5-primed human eosinophils completely inhibits Siglec-8-mediated apoptosis and ROS production. These responses require intracellular activation of reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and a subset of protein tyrosine kinases, thus identifying a novel signaling pathway by which Siglec-8 actually functions as an activating receptor.
METHODS Eosinophil isolation
'Written informed consent for blood donation (up to 180 mL) was obtained by using an institutional review board-approved protocol at the Northwestern University Feinberg School of Medicine. Eosinophils from mildly allergic and nonallergic donors were purified from peripheral blood by using density gradient centrifugation, erythrocyte hypotonic lysis, and CD16 immunomagnetic negative selection (Miltenyi Biotech, San Diego, Calif), as previously described. 20 Purity and viability were consistently greater than 95%, as determined by using flow cytometry and 49-6-diamidino-2-pheynlindole dihydrochloride (DAPI) exclusion (Thermo Scientific, Waltham, Mass). Cells were cultured in RPMI 1640 medium containing 10% FCS and antibiotics (''complete medium''; all from Thermo Scientific) with or without 30 ng/mL rhIL-5 (R&D Systems, Minneapolis, Minn) for 18 to 24 hours, as indicated.
Drugs and mAb reagents
LY294002, SB203580, SP600125, and NSC 23766 were obtained from Selleckchem (Houston, Tex), mitoTempo and catalase were obtained from Sigma-Aldrich (St Louis, Mo), and carboxy-PTIO was obtained from Cayman Chemical (Ann Arbor, Mich). Fluorochrome-conjugated or unconjugated mouse IgG 1 blocking mAbs against human CD11b (clone ICRF44), CD18 (clone TS1/18), and activated CD11b (clone CBRM1/5), as well as an irrelevant mouse IgG 1 mAb and human IgG 4 control mAbs, were obtained from BioLegend (San Diego, Calif). Mouse IgG 1 anti-Siglec-8 mAb (clone 2C4) was used, as previously reported. 8 Chimeric IgG 4 anti-Siglec-8 mAb (clone c2E2, made from clone 2E2 that recognizes the same epitope as 2C4 10 ) was generated by molecularly swapping the mouse IgG 1 Fc region with human IgG 4 . In addition, c2E2 F(ab9) 2 fragments were generated by using immobilized pepsin (Thermo Scientific). Briefly, c2E2 was initially dialyzed overnight against 20 mmol/L sodium acetate and 100 mmol/L sodium chloride (pH 4.5) and then incubated with immobilized pepsin for 4 hours at 378C. The pepsin reaction was stopped by increasing the pH to 8.0. Nondigested and Fc fragments were removed by using MabSelect Resin (GE Healthcare Life Sciences, Pittsburgh, Pa) and size exclusion chromatography. Both c2E2 and c2E2 F(ab9) 2 fragments were kindly provided by John Leung and Nenad Tomasevic (Allakos, San Carlos, Calif). Clear, flat-bottom, 48-well Falcon tissue culture-treated plates were obtained from Thermo Fisher Scientific (Pittsburgh, Pa).
Eosinophil adhesion assay
Freshly isolated or rhIL-5-primed eosinophils (5 3 10 4 ) were incubated for 1 hour at 378C in complete medium with 2.5 mg/mL mAb 2C4 or IgG 1 control in a 48-well tissue culture-treated plate. Changes in morphology were assessed by using an Olympus 1X71 CellSens Light Microscope (316; Olympus, Tokyo, Japan). To quantify adhesion, freshly isolated or rhIL-5-primed eosinophils (5 3 10 4 ) were incubated with either mAb 2C4, IgG 1 control, a specific artificial Siglec-8 ligand (a polyacrylamide polymer decorated with 69-sulfo-sialyl-N-acetyl-D-lactosamine-polyacrylamide [69-O-Sulfo-39SLN-PAA]), or a control PAA polymer decorated instead with Lewis X (Lewis X-PAA), 21 both kindly provided by Corwin Nycholat (Scripps Research Institute, La Jolla, Calif) for 2 hours at 378C in complete medium. Nonadherent cells were removed by pipetting up and down twice and collected, and their numbers were determined by using a Cellometer AutoX4 Cell Counter (Nexcelom Biosciences, Lawrence, Mass). Percentage adhesion was calculated by comparing the number of nonadherent cells to the total number of cells added.
Eosinophil degranulation assay
rhIL-5-primed eosinophils (5 3 10 4 ) were incubated in complete medium at 378C with mAb 2C4 or IgG 1 control for various times. Next, eosinophil cationic protein (ECP) levels in supernatants diluted 1:10 with assay buffer were assessed with the Mesacup ECP Test (MLB, Woburn, Mass), according to the manufacturer's instructions, and normalized to nanograms per milliliter per 10 6 cells, with the limit of detection of the assay being 0.125 ng/mL. Percentage degranulation was calculated by normalizing to total eosinophil ECP levels.
Eosinophil phosphoproteomics
Freshly isolated or rhIL-5-primed eosinophils (15 3 10 6 ) were incubated for 15 minutes at 378C in complete medium with mAb 2C4 or IgG 1 control, after which cell pellets were collected by means of centrifugation at 140g for 5 minutes at 48C. Pellets were solubilized by using 3 freeze-thaw cycles in 8 mol/L urea, yielding between 150 and 200 mg of total protein for each treatment, as previously described. 22 Protein extracts were reduced and alkylated before digestion with trypsin (Promega, Madison, Wis). Resulting peptides were desalted with Sep-Pak C18 cartridge chromatography (Waters, Milford, Mass). The desalted peptides were fractionated by means of weak cation exchange chromatography (PolySULFOETHYL A HPLC; PolyLC, Columbia, Md), and the bound peptides were fractionated by means of elution with potassium chloride. 23 Fractions were combined into 4 pools, dried, and incubated with PHOS-Select Iron Affinity Gel (Sigma-Aldrich). Nonphosphorylated peptides were collected in the unbound material, and phosphopeptides were eluted with ammonium hydroxide. The resulting pools of phosphopeptides and nonphosphopeptides were analyzed by using liquid chromatography-tandem mass spectrometry (Orbitrap Fusion Lumos, Thermo Scientific).
human proteins (UniProt, www.uniprot.org; November 5, 2015) . Protein identifications were obtained by using ProteoIQ (PREMIER Biosoft, Palo Alto, Calif). Protein identifications were scored and filtered with a minimum peptide probability of 0.05% and a minimum protein group probability of 0.5%. Gene ontology (GO) analysis of biological processes associated with the identified proteins was performed by using the Database for Annotation, Visualization and Integrated Discovery. 24, 25 Data are presented by selecting all of the GO categories with P values of less than .0001.
Apoptosis assay
rhIL-5-primed eosinophils (2 3 10 5 ) were incubated for 18 to 24 hours at 378C with mAb 2C4, IgG 1 control, mAb c2E2, IgG 4 control, c2E2 F(ab9) 2 , 69-O-Sulfo-39SLN-PAA, or Lewis X-PAA, as previously described, 8 at which point apoptosis was assessed by means of flow cytometry after fluorescein isothiocyanate-Annexin V (BD Biosciences, San Jose, Calif) and DAPI (Thermo Scientific) labeling per the manufacturer's instructions.
ROS assay
Eosinophil ROS production was measured by using the ROS-ID Total ROS detection kit (Enzo Life Sciences, Farmingdale, NY). rhIL-5-primed eosinophils (5 3 10 5 ) were incubated with mAb 2C4, IgG 1 control, mAb c2E2, IgG 4 control, c2E2 F(ab9) 2 , 69-O-Sulfo-39SLN-PAA, or Lewis X-PAA at 378C for the indicated time points, and ROS levels were assessed per the manufacturer's instructions. Levels of ROS generation were normalized to the no-treatment group or 2C4 alone (x5100%) as indicated within each experiment.
Flow cytometry
Flow cytometric measurements were made with a BD LSR II flow cytometer (BD Biosciences) and FlowJo software (version 10; TreeStar, Ashland, Ore). In brief, freshly isolated or rhIL-5-primed eosinophils (2 3 10 5 ) were incubated for the indicated time points with mAb 2C4, IgG 1 control, mAb c2E2, IgG 4 control, c2E2 F(ab9) 2 , 69-O-Sulfo-39SLN-PAA, or Lewis X-PAA at 378C in complete medium. CD11b surface expression was measured by using a phycoerythrin-conjugated mouse anti-human mAb, whereas levels of CD18 and activated CD11b were detected by using fluorescein isothiocyanate-conjugated mAbs. 
Stress and apoptosis array

Western blot analysis
rhIL-5-primed eosinophils (5 3 10 5 ) were incubated in complete medium at 378C with mAb 2C4 or IgG 1 control for various time points. Next, 23 Laemmli buffer (Bio-Rad Laboratories, Hercules, Calif) was used to isolate total protein from cell lysates, which was then electrophoresed through mini-PROTEAN TGX precast gels and transferred to Immun-Blot Low Fluorescence PVDF Membranes by using the Trans-Blot SD Semi-Dry Transfer Cell (Bio-Rad Laboratories), according to the manufacturer's guidelines. After blocking with Odyssey Blocking Buffer (TBS; LI-COR, Lincoln, Neb), membranes were incubated overnight with various mAbs or polyclonal antibodies (1:500 to 1:1000 in 5% BSA in TBS-Tween): phospho-Akt, Akt, phospho-p38, p38, phospho-c-Jun N-terminal kinase (JNK)/stress-activated protein kinase, and JNK/stress-activated protein kinase (Cell Signaling). Specific binding of these antibodies was detected with infrared dye (IRDye) 680RD-or 800RD-conjugated secondary antibodies (LI-COR) by using the Odyssey Imaging System (LI-COR).
Statistical analysis
Data are presented as means 6 SEMs, unless otherwise indicated. Statistical significance was determined by using 1-way ANOVA with GraphPad Prism 6.0e (GraphPad Software, La Jolla Calif). Inhibitory concentration of 50% (IC 50 ) values were calculated by using nonlinear fit, and outliers were determined by using the Grubbs test. Values were considered significant at a P value of less than .05.
RESULTS
Siglec-8 engagement in the presence or absence of IL-5 induces changes in eosinophil morphology and promotes cell adhesion
Initial experiments to identify molecules involved in the function of Siglec-8 in human eosinophils led to the fortuitous observation that mAb engagement of Siglec-8 on IL-5-primed eosinophils promoted eosinophil sticking to tissue culture plates. Freshly isolated or IL-5-primed eosinophils were incubated with mAb 2C4 or IgG 1 control for 1 hour and morphologic changes were assessed by using light microscopy to directly investigate the effect of Siglec-8 engagement on eosinophil adhesion. As shown in Fig 1, A, the addition of an antibody to Siglec-8 triggered eosinophil flattening and spreading, although only in IL-5-primed cells. Subsequently, analysis of the eosinophil phosphoproteome using liquid chromatography-tandem mass spectrometry identified 237 proteins that were differentially phosphorylated after Siglec-8 engagement (see Table E1 in this article's Online Repository at www.jacionline.org). A GO analysis revealed that some of these proteins are linked to pathways associated with cell adhesion and cytoskeletal organization (Fig 1,  B) , suggesting that Siglec-8 engagement on IL-5-primed eosinophils activates signaling pathways associated with cell adhesion.
Siglec-8 engagement activates CD11b/ CD18-dependent eosinophil adhesion in an IL-5-dependent manner
On their surfaces, eosinophils express a number of adhesion molecules. In particular, b 2 -integrins are known to mediate eosinophil adhesion to various surfaces, and activation of adhesiveness in eosinophils is often associated with rapid upregulation of surface expression of certain b 2 -integrins. [26] [27] [28] Indeed, after 60 and 120 minutes of incubation with mAb 2C4 FIG 1. Siglec-8 antibody-induced changes in eosinophil morphology and phosphoproteomics in the presence or absence of IL-5 priming. A, Freshly isolated or overnight IL-5-primed eosinophils were incubated with mAb 2C4 or IgG 1 control for 1 hour, and adhesion and cell spreading were documented by using light microscopy. Images were taken at 316 magnification, and data are representative of 3 separate experiments with identical results. B, Phosphorylated proteins were identified by using mass spectrometry in lysates of IL-5-primed human eosinophils cultured with mAb 2C4 or IgG 1 control for 15 minutes. Biological processes associated with Siglec-8 engagement on primary eosinophils were determined by using functional enrichment analysis by GO terms, as described in the Methods section. Data are from a single experiment, and numbers of identified phosphoproteins within each GO category are indicated. = J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 6 or Siglec-8 synthetic ligand, respectively, marked upregulation of CD11b and CD18 was detected on the surfaces of eosinophils, and this effect, like adhesion and cell spreading, was dependent on IL-5 priming (Fig 2, A, and see Fig E1, A, in this article's Online Repository at www.jacionline.org). Additionally, 2C4 promoted activation of CD11b (detected by using a conformational epitope-specific mAb) that was also dependent on IL-5 priming (Fig 2, B) . When formally quantified, significantly enhanced adhesion (62% 6 6.8% with 2C4 and 48% 6 1.9% with Siglec-8 synthetic ligand) was observed 2 hours after Siglec-8 engagement with IL-5-primed but not unprimed eosinophils (36.5% 6 5.5% adhesion), and IL-5 priming alone had very little if any effect on adhesion (Fig 2, C , and see Fig E1, B) . To determine whether adhesion was b 2 -integrin dependent, IL-5-primed eosinophils were preincubated with CD11b or CD18 blocking mAbs, reducing Siglec-8-mediated eosinophil adhesion to 38.3% 6 2.3% and 16.8% 6 4.4%, respectively (Fig 2, C) . These data demonstrate that Siglec-8 engagement triggers a rapid upregulation and activation of eosinophil CD11b-and CD11b/CD18-dependent adhesion in IL-5-primed eosinophils but not in nonprimed cells. . C, Freshly isolated or overnight IL-5-primed eosinophils were incubated with mAb 2C4 or IgG 1 control for 2 hours. Additionally, overnight IL-5-primed eosinophils were incubated with 10 mg/mL CD11b or CD18 blocking antibody for 1 hour, as indicated before the addition of mAb 2C4 or IgG 1 control for 2 hours. After removal of nonadherent cells, percentage eosinophil adhesion was determined. *P < .05, **P < .01, ***P < .001, and ****P < .0001 (n 5 3-5, 1-way ANOVA).
A B FIG 3.
Siglec-8-mediated eosinophil ROS generation and apoptosis are b 2 -integrin dependent. A, Eosinophils were incubated overnight with IL-5, and then 10 mg/mL CD11b or CD18 blocking antibody was added for 1 hour before addition of mAb 2C4 or IgG 1 control. ROS was assessed 1 hour later, and total ROS production was normalized to levels obtained with 2C4 mAb alone (geometric mean fluorescence intensity [GMFI]: 418 6 97) after subtraction of background ROS levels (GMFI: 146 6 75). B, Eosinophils were incubated as in panel Fig 3, A. Apoptosis was then assessed 18 to 24 hours later and was normalized to levels of cell death seen with mAb 2C4 treatment alone (96% 6 0.13% apoptosis) after subtraction of baseline apoptosis seen in the no-treatment group (34% 6 5% apoptosis). *P < .05 and ****P < .0001 (n 5 3-4, 1-way ANOVA).
Because eosinophil activation and adhesion can result in degranulation, 26, 29 supernatants of IL-5-primed eosinophils were assayed at the indicated time points with or without 2C4 for the presence of ECP by using ELISA. As shown in Fig E2 in this article's Online Repository at www.jacionline.org, ECP levels were no different in the presence or absence of mAb 2C4. Therefore these data suggest that Siglec-8-induced adhesion does not result in degranulation or necrosis above background, at least during the time frame studied, and that granule protein release cannot be responsible for secondarily enhancing adhesion.
Siglec-8-mediated eosinophil ROS production and apoptosis are b 2 -integrin dependent
Previously, it was shown that antibody ligation of Siglec-8 on IL-5-primed eosinophils led to ROS production and apoptosis, 12 suggesting a downstream activation response, but the intervening pathways contributing to this process remain poorly defined. Given the data in Figs 1 and 2 , experiments were performed to determine whether adhesion was necessary for ROS production and apoptosis. As shown in Fig 3, Siglec-8-mediated eosinophil ROS production and apoptosis were both significantly inhibited in the presence of CD18 blocking antibody (approximately 65% and 90% inhibition, respectively), whereas CD11b blocking antibody only partially (by approximately 40%) and nonsignificantly inhibited ROS generation and had no effect on apoptosis. Taken together, these data demonstrate that Siglec-8-mediated generation of ROS and apoptosis require functional eosinophil b 2 -integrins.
Siglec-8 mAb-mediated effects on integrindependent processes, ROS production, and apoptosis are independent of Fc binding
Given the unanticipated activation of eosinophils by Siglec-8 engagement with mAb and given the expression of the FcgRIIA isoform on eosinophils, 30 it was important to rule out involvement of FcgRIIA after Siglec-8 engagement by mAbs. Therefore, in addition to exposure to mAb 2C4 and IgG 1 control, we incubated eosinophils with a chimeric human IgG 4 anti-Siglec-8 mAb c2E2 or c2E2 F(ab9) 2 fragment and show that CD11b upregulation, ROS generation, and eosinophil apoptosis are indeed Siglec-8 specific and independent of Fc binding (see Fig E3 in this article' s Online Repository at www.jacionline.org).
Siglec-8 engagement leads to NADPH oxidase activation in IL-5-primed eosinophils
Previously, it was shown that antibody ligation of Siglec-8 on IL-5-primed eosinophils led to ROS production and that this ROS production was necessary for cell death, but the kinetics of ROS generation and its source remain unknown. 12 As shown in Fig 4, A, and Fig E4, A, Eosinophils were incubated overnight with IL-5 before addition of mAb 2C4 or IgG 1 control, and total ROS levels were measured at various times for up to 3 hours. Total ROS production was normalized to the no-treatment group (geometric mean fluorescence intensity [GMFI]: 79 6 6), as in Fig 3. B and C, Eosinophils were incubated overnight with IL-5, and then catalase (superoxide scavenger) or NSC 23766 (Rac GTPase inhibitor) was added for 1 hour before addition of mAb 2C4 or IgG 1 control. Apoptosis was assessed 18 to 24 hours later, as in Fig 3. *P < .05, **P < .01, ***P < .001, and ****P < .0001 (n 5 3-4, 1-way ANOVA).
J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 6 A B D E C www.jacionline.org, after Siglec-8 engagement, there was a time-dependent increase in Siglec-8-mediated eosinophil ROS production that peaked at 60 minutes with the Siglec-8 mAb and at 180 minutes with the synthetic Siglec-8 ligand. The source of ROS production that resulted in apoptosis (see Fig  E4, B) after Siglec-8 engagement of IL-5-primed eosinophils was examined by using intracellular and extracellular ROS scavengers and a Rac GTPase inhibitor. As shown in Fig 4, 31, 32 Taken together, these data suggest that Siglec-8-mediated ROS generation in IL-5-primed eosinophils is through activation of NADPH oxidase rather than mitochondrial sources.
Siglec-8 engagement induces phosphorylation of various intracellular stress proteins in a b 2 -integrin-dependent manner
To expand on data generated in Fig 1, B, and to identify specific proteins involved in Siglec-8-mediated signaling and eosinophil apoptosis, we used a phosphoprotein array that included a range of stress proteins. As shown in Fig 5, A, exposure of IL-5-primed eosinophils to mAb 2C4 led to enhanced phosphorylation of heat shock protein 27 and cleavage of caspase-3 and poly-ADP ribose polymerase, molecules shown to be regulated by phosphatidylinositide 3-kinase (PI3K)/Akt, p38 mitogenactivated protein kinase (p38), and c-Jun N-terminal kinases (JNK1/2), which in turn can be regulated by b 2 -integrins and oxidative stress. 33, 34 Therefore subsequent experiments were performed to explore whether Akt, p38, and JNK1/2 are phosphorylated at various time points after Siglec-8 engagement on IL-5-primed eosinophils. As displayed in Fig 5, B-E, Siglec-8 engagement led to rapid and statistically significant increases in phosphorylation of Akt, p38, and JNK1 but not JNK2, and phosphorylation of these proteins was prevented by blocking b 2 -integrins. Pharmacologic inhibitors were used to establish the necessity of these signaling proteins in Siglec-8 function.
As shown in Fig 6, A-C [35] [36] [37] Furthermore, when used at IC 50 concentrations, only LY294002 and SB203580 were able to significantly block Siglec-8-mediated ROS generation (Fig 6,  D) , suggesting that Akt and p38 act upstream of ROS production. These data show that Akt, p38, and JNK1 are necessary for Siglec-8 signaling and downstream function in IL-5-primed eosinophils, providing further evidence in support of the conclusion that Siglec-8 functions as an activating receptor.
DISCUSSION
CD33-related Siglecs are thought to negatively regulate inflammatory responses, but the proteins mediating the downstream functional outcomes after receptor engagement are not fully characterized, especially for Siglec-8. 38 The present work extends previous findings that Siglec-8 engagement with mAb or a synthetic ligand induces eosinophil apoptosis in IL-5-activated eosinophils [11] [12] [13] [14] 21 by showing that Siglec-8 engagement, depending on the priming status of the cell, rapidly induces patterns of phosphoprotein expression consistent with activation of signaling pathways associated with adhesion, which is further corroborated by finding rapid enhancement of b 2 -integrin-dependent eosinophil adhesion. Previously, it was demonstrated that in the presence of IL-5, GM-CSF, or IL-33 priming, Siglec-8 engagement leads to ROS generation and enhances eosinophil apoptosis without causing degranulation, the latter differing from what can be seen with briefer exposure to priming cytokines. 10, 13, 14, 19 In this study IL-5 priming was necessary to cause rapid and pronounced Siglec-8 engagement-mediated upregulation of eosinophil surface CD11b/CD18, activation of surface CD11b, and adhesion to and spreading on tissue culture plates, processes that were effectively inhibited by CD11b and CD18 blocking mAbs. Although the exact ligand or ligands responsible for adhesion in the assay used were not explored, FBS used in the culture medium contains numerous proteins, including known ligands for CD11b/CD18 (vitronectin, fibrinogen, periostin, and even albumin). 39, 40 Therefore we presume that proteins in the media are coated onto the tissue culture dish surface, providing substrates for CD11b/CD18 eosinophil adhesion.
The finding that Siglec-8 engagement upregulates CD11b/ CD18 surface expression, activates CD11b, and promotes eosinophil adhesion and spreading differs significantly from data on the mouse neutrophil Siglec-E presented by McMillan et al, 41 showing that engagement of mouse neutrophil Siglec-E B, Eosinophils were treated as in panel Fig 5, A, and levels of selected phosphorylated intracellular proteins were measured by using Western blotting at various times, as indicated. Levels of total protein were used as loading controls. Shown are data from 1 experiment representative of at least 3 experiments. C, Bar graphs show average quantified levels of phosphorylated proteins from replicate experiments. *P < .05, **P < .01, and ***P < .001 (n 5 3-4, 1-way ANOVA). D, Eosinophils were incubated overnight with IL-5, and then 10 mg/mL CD18 blocking antibody was added for 1 hour before addition of mAb 2C4 or IgG 1 control for 1 hour. Levels of selected phosphorylated intracellular proteins were measured by means of Western blotting. Levels of total protein were used as loading controls. Shown are data from 1 experiment representative of at least 3 experiments. E, Bar graphs show average quantified levels of phosphorylated proteins from replicate experiments. *P < .05, **P < .01, and ****P < .0001 (n 5 3, 1-way ANOVA). In panels B and D, ''not'' indicates the no-treatment group.
=
J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 6 can negatively regulate CD11b-dependent neutrophil recruitment to the lung but has no effect on neutrophil CD11b surface expression or on CD11b-mediated neutrophil adhesion, which is in accordance with the typical notion of Siglecs functioning as inhibitory receptors. Whether this occurs in eosinophils through its ITIM or immunoreceptor tyrosine-based switch motif domain 8 remains unknown and is the basis of ongoing studies.
Although the requirement for prior IL-5 exposure to allow Siglec-8 engagement to then activate integrins and all the downstream activation steps leading to eosinophil apoptosis is now better delineated, the biochemical events responsible for its IL-5 dependence are less clear. One likely explanation supported by the literature is that IL-5 provides preactivation and repositioning of integrins within cellular microdomains. For example, in freshly isolated blood eosinophils CD11b/CD18 primarily exists in a bent inactive conformation. However, IL-5 priming of eosinophils results in a high-activity conformation of CD11b/CD18, enhancing eosinophil adhesion. 42, 43 Han and Mosher 44 showed that IL-5 priming promotes eosinophil polarization, where the nucleus and granules move in opposite directions. Additionally, IL-5 priming promotes localization and clustering of adhesion receptors, facilitating ''outside-in'' signaling of the integrin by means of efficient coupling to downstream signaling proteins. Therefore it is tempting to speculate that when eosinophils are exposed to IL-5 family cytokines, eosinophil adhesion and polarization promote both CD11b/CD18 and Siglec-8 clustering in the nucleopod, bringing Siglec-8 in proximity to CD11b/CD18 and facilitating downstream signaling processes that allow induction of Siglec-8-mediated eosinophil apoptosis on Siglec-8 engagement by its ligand. phox , and Rac GTPase) components. Upon cell stimulation, Rac GTPase binds the cytosolic components and promotes membrane translocation and NADPH oxidase activation. 47 The present studies show that b 2 -integrin activation and adhesion are necessary for Siglec-8-mediated eosinophil ROS production and that scavenging of extracellular ROS or inhibition of Rac GTPase activity prevents Siglec-8-mediated apoptosis but only in IL-5-primed cells. These data are in agreement with work by McMillan et al 48 showing that Siglec-E on mouse neutrophils positively regulates NADPH oxidase activity and ROS production in a b 2 -integrin-dependent manner.
Siglec-8-mediated eosinophil apoptosis was inhibited by LY294002, and Siglec-8 engagement led to a time-dependent increase in Akt phosphorylation. Similar Siglec-related observations were made in platelets, where Siglec-7-mediated apoptosis was inhibited in the presence of the inhibitor LY294002. 49 Additionally, Siglec-E-mediated ROS production in mouse neutrophils required Akt activation. 48 Akt is in a family of serine/threonine kinases that play a crucial role in regulating cell metabolism, growth, proliferation, and apoptosis in a PI3K-dependent manner. 50 A common function attributed to Akt is its ability to inhibit apoptosis by negatively regulating proapoptotic molecules and promoting cell-cycle progression by controlling energy metabolism. 51 However, Nogueira et al 52 challenge this dogma and show that activation of Akt can promote cell apoptosis by increasing oxidative stress. They report that activated Akt induces ROS-dependent apoptosis of mouse fibroblasts by increasing oxygen consumption and impairing function of ROS scavengers. The present data are in agreement with this report and suggest that Akt activation after Siglec-8 engagement is upstream of ROS production and necessary for Siglec-8-mediated eosinophil ROS production and apoptosis. Therefore it seems likely that active Akt negatively regulates eosinophil ROS scavengers and that this is a key molecular event that triggers accumulation of ROS, leading to eosinophil apoptosis after Siglec-8 engagement.
Mitogen-activated protein kinases are an evolutionarily conserved family of serine/threonine kinases that include extracellular signal-regulated kinase 1/2, JNK, and p38, which have been shown to control a number of intracellular processes, including cell transcription, proliferation, survival, and apoptosis. 33, 53 The present work strongly suggests that Siglec-8-mediated eosinophil apoptosis requires activation of JNK1 and p38, and activation of JNK1 is downstream of Siglec-8-mediated ROS production. This is in line with multiple studies reporting that ROS can activate JNK and promote cell apoptosis in various cell types. 34 Additionally, in eosinophils it has been reported that ROS can activate JNK and promote apoptosis. 54 Unexpected was our observation that pharmacologic inhibition of p38 inhibited Siglec-8-mediated ROS production, suggesting that p38 acts upstream of NADPH oxidase. Although it is traditionally thought that oxidative stress activates p38 to promote cell death, 34 other lines of evidence support the concept that p38 regulates NADPH oxidase activity in granulocytes. In fact, activation of eosinophils and neutrophils with a variety of stimuli (formyl-peptides, endotoxin, phorbol esters) leads to activation of p38, which is necessary for NADPH oxidase activation and ROS generation, [55] [56] [57] [58] [59] further supporting our observation that p38 mediates NADPH oxidase activity after Siglec-8 engagement. Unlike Siglec-E engagement on mouse neutrophils, which negatively regulates p38 phosphorylation, current findings are in agreement with other data showing Siglec-5/Siglec-14 engagement promotes endotoxin or group B streptococcus-dependent phosphorylation of p38. 48, 60 Although speculative, the current findings might have implications for our understanding of the function of Siglec-8 on eosinophils in health and disease, as well as the safety and suitability of Siglec-8 as a therapeutic target. Regarding the former, one possible scenario suggested by the finding that Siglec-8 engagement activates adhesion, ROS generation, and death could be that when eosinophils encounter a natural ligand, such as an endogenous sialoside-containing structure in the airways, 61 the interaction selectively facilitates eosinophil attachment, leading to removal of the eosinophil through apoptosis. Regarding potential safety concerns that might arise when Siglec-8 is ''activated'' on a cytokine-primed eosinophil in vivo by a therapeutic agent, such as an antibody, one might see a rapid decrease in numbers of circulating eosinophils through margination if b 2 -integrins are activated, but at the same time, Siglec-8 engagement, even of IL-5-primed cells, does not result in detectable degranulation or necrosis, an important concern that has been rightfully raised when trying to eliminate eosinophils for therapeutic benefit. 62 Clinical trials with humanized Siglec-8 mAbs have already begun, with at least 1 phase I study completed and phase II studies underway (https:// clinicaltrials.gov/ct2/results?cond5&term5allakos& cntry15&state15&recrs5), so more information regarding safety and efficacy should be forthcoming.
In conclusion, the work reported here has uncovered a novel mechanism and pathway by which IL-5-primed eosinophils undergo cell death. After Siglec-8 engagement, downstream activation of b 2 -integrins promotes enhanced eosinophil adhesion, which is necessary for NADPH oxidase activation, ROS generation, activation of a subset of tyrosine kinases, and ultimately eosinophil apoptosis (Fig 7) . Studies using F(ab9) 2 versions of Siglec-8 mAb and polymeric Siglec-8 glycan ligands confirmed that specific engagement of Siglec-8, independent of any possible role for FcgR on eosinophils, was responsible for the observed biological activities. Our current results challenge the established dogma implicating CD33-related Siglecs as inhibitory receptors and provides a novel mechanism for regulation of Siglec-8 function in cytokine-primed human eosinophils.
